Ola Camber
Chief Executive Officer bei Camber Consulting AB
Profil
Ola Camber is currently the Chief Executive Officer & Director at Camber Consulting AB, Clinstorage AB, Clinproducts AB, and a Member-Review Panel at Vetenskapsrådet.
In the past, he worked as the Director of Pharmaceutical Research & Development at Pharmacia AB, Director at Karyon-CTT Oy, Director at Eribis Pharmaceuticals AB, Independent Director at Ziccum AB, Vice President-Pharmaceutical Development at Athera Biotechnologies AB, Vice President-Drug Development at AstraZeneca AB, Professor at the University of Uppsala, Vice President-Drug Development at InDex Pharmaceuticals Holding AB, Principal at Moberg Pharma AB, Development Manager at Biosergen AS, and Head-Pharmaceutical Research & Development at Vicore Pharma Holding AB.
Aktive Positionen von Ola Camber
| Unternehmen | Position | Beginn |
|---|---|---|
| Camber Consulting AB | Chief Executive Officer | - |
Clinstorage AB
 Clinstorage AB Miscellaneous Commercial ServicesCommercial Services Clinstorage AB is a Swedish company that specializes in packaging, labeling, and managing the cold chain logistics of drugs. The private company is based in Stockholm, Sweden. The CEO of the company is Ola Camber. | Chief Executive Officer | - |
| Clinproducts AB | Chief Executive Officer | - |
| Vetenskapsrådet | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Ola Camber
| Unternehmen | Position | Ende |
|---|---|---|
Eribis Pharmaceuticals AB
 Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Director/Board Member | - |
| VICORE PHARMA HOLDING AB | Chief Tech/Sci/R&D Officer | - |
| ZICCUM AB | Director/Board Member | - |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Corporate Officer/Principal | - |
| MOBERG PHARMA AB | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| INDEX PHARMACEUTICALS HOLDING AB | Health Technology |
| MOBERG PHARMA AB | Health Technology |
| VICORE PHARMA HOLDING AB | Health Technology |
| ZICCUM AB | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| Pharmacia AB | Health Technology |
Karyon-CTT Oy
 Karyon-CTT Oy Miscellaneous Commercial ServicesCommercial Services Karyon-CTT Oy discovers and develops novel and innovative peptide-based tumor targeting systems. Its Targeting Units (TU) are intended for delivery of diagnostic imaging agents or therapeutic compounds to cancer tissue. The company was founded in 2006 and is headquartered in Helsinki, Finland. | Commercial Services |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
Eribis Pharmaceuticals AB
Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Health Technology |
| Vetenskapsrådet | |
| Camber Consulting AB | |
Clinstorage AB
Clinstorage AB Miscellaneous Commercial ServicesCommercial Services Clinstorage AB is a Swedish company that specializes in packaging, labeling, and managing the cold chain logistics of drugs. The private company is based in Stockholm, Sweden. The CEO of the company is Ola Camber. | Commercial Services |
| Clinproducts AB |
